Statement II

Primary Health Center opened in the Country during last three years and proposed to be opened during the current financial year

SI. No.	Stale/UTs	Opened during 1998-	1999-2000	2000-2001	Targets 2001-2002
1	Andhra Pradesh	1	50	—	93
2.	Arunachal	—	13	7	0
3.	Assam	—	—	—	26
4.	Bihar	—	—	—	—
5.	Chhattisgarh	—	—	—	—
6.	Goa	—	—	2	2
7.	Gujarat	7	17	17	17
8.	Haryana	1	—	—	4
9.	Himachal	—	—	—	0
10.	J&K	—	—	0	—
11.	Jharkhand	—	—	—	—
12.	Karnataka	75	—	—	0
13.	Kerala	2	—	—	0
14.	Madhya Pradesh	—	—	—	—
15.	Maharashtra	—	63	6	16
16.	Manipur	—	—	—	0
17.	Meghalaya	—	—	—	0
18.	Mizoram	—	—	3	0
19.	Nagaland	—	13	—	6
20.	Orissa	—	—	—	0
21.	Punjab	—	—	—	0
22.	Rajasthan	16	12	—	0
23.	Sikkim	—	—	—	0
24.	Tamil Nadu	—	—	—	0
25.	Tripura	—	—	—	10
26.	Ultar Pradesh	—	—	—	—
27.	Uttaranchal	—	—	—	—
28.	West Bengal	—	—	—	41
29.	A & N Islands	—	1	—	0
30.	Chandigarh	—	—	—	0
31.	D & N Haveli	—	—	—	0
32.	Daman & Diu	—	—	—	0
33.	Delhi	—	—	—	6
34.	Lakshadweep	—	—	—	0
35.	Pondicherry	—	—	—	0
	TOTAL:	102	169	35	221

Compromise on quality of drugs

2163. SHRI MANOJ BHATTACHARYA:—Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether quality or standard of drugs are being compromised due to the wide practice of third party manufacturing or manufacturing under loan licence system by many reputed companies;

(b) if so, whether Government envisage any measures to curb this; and

(c) if so, the measures being contemplated?

THE MINISTER OF HEALTH AND FAMILY WELFARE (DR. C.P. THAKUR): (a) As per the feed back available from State Licensing Authorities of Maharashtra, Orissa, Kerala, Goa, Karnataka, Delhi, Rajasthan, Chandigarh UT, Lakshadweep, Sikkim, no such incidence has come to their notice where quality or standards of drugs are being compromised due to third party manufacturing or manufacturing under loan licence system by reputed companies.

(b) and (c) The Drugs Controller General of India has asked all Pharmaceuticals, Industry Associations to convey any specific information about alleged spawning of fake drug trade due to misuse of loan license activity. All State Drugs Control Authorities have also been directed to convey specific information about such linkage, if any, observed by them in their State.

Departure from process patent regime

2164. SHRI MANOJ BHATTACHARYA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state :

(a) whether a departure from the process patent regime in respect of the manufacturing and availability of the essential drugS will adversely affect the prices of drug formulations; and

(b) if so, the concrete measures Government are contemplating to avert such serious problem?

THE MINISTER OF HEALTH AND FAMILY WELFARE (DR.C. P.THAKUR): (a) and (b) While the actual impact of change from the process patent regime for pharmaceuticals to a product patent regime cannot be gauged as there are no product patents at present for pharmaceutical products, it is generally felt that